Dual-pronged nano-drug delivery using plant virus-like particles
使用植物病毒样颗粒的双管齐下纳米药物输送
基本信息
- 批准号:10700990
- 负责人:
- 金额:$ 36.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:4T1BindingBiodistributionBiological AssayBlocking AntibodiesBloodBreast Cancer PatientCanis familiarisCellsClinicalClinical TrialsCombined Modality TherapyCompanionsCowpea Mosaic VirusesDataDevelopmentDiseaseDisseminated Malignant NeoplasmDistant MetastasisDoseDrug Delivery SystemsEngineeringEventExtracellular MatrixFemaleFlow CytometryFundingFutureGenomicsGoalsHumanImmuneImmune checkpoint inhibitorImmune systemImmunologicsImmunotherapyIn VitroInflammationInnate Immune SystemIntravenousLibrariesLifeLinkMalignant NeoplasmsMammary NeoplasmsMolecularMonitorMonoclonal AntibodiesMyelogenousNeoplasm MetastasisPatientsPatternPattern recognition receptorPeptidesPharmacologyPlant VirusesPrognosisPropertyProteinsRadiationRecurrenceResearchResourcesS100A9 geneSafetyScheduleSignal TransductionSiteSpainSpecificityT-LymphocyteTLR2 geneTestingTimeTissuesToll-like receptorsToxic effectTumor AntigensTumor ImmunityTumor MarkersVirus-like particleanti-PD-L1biophysical propertiescancer immunotherapycandidate identificationcandidate selectioncarcinogenesischeckpoint therapychemotherapyeffector T cellefficacy evaluationimmune modulating agentsimmunoregulationin situ vaccinationin vivoinsightmalignant breast neoplasmmouse modelnanodrugnanomedicinenanoparticleneoantigenspathogenpersonalized approachpharmacologicpreclinical developmentpreventprogrammed cell death ligand 1receptorresidencesafety assessmentsynergismtargeted treatmenttreatment responsetriple-negative invasive breast carcinomatumortumor growthtumor microenvironmenttumorigenesis
项目摘要
Summary
This R01 renewal application is focused on triple negative breast cancer (TNBC), which is an aggressive life-
threatening disease with poor prognosis and increased likelihood of recurrence and distant metastasis.
Advances in cancer immunotherapy have demonstrated that modulation of the patient’s immune system can
result in dramatic antitumor activity. The most promising immunotherapy approaches are those that are
personalized and take advantage of the unique neoantigens within each patient’s tumor. Toward this goal, we
developed a plant virus nanoparticle immunotherapy approach that activates innate immune cells within
the tumor microenvironment (TME) to launch adaptive, systemic, and durable antitumor immunity.
Specifically, intratumorally injected cowpea mosaic virus (CPMV) demonstrates potent efficacy in multiple mouse
models, incl. TNBC. Trials in companion dogs with breast cancer also demonstrate potent antitumor efficacy.
During the previous funding cycle, we gained insights into the mechanism of action and demonstrated that
CPMV is recognized by pathogen-associated molecular pattern (PAMP) receptors that detect danger signals
and activate the innate immune system; specifically, CPMV is recognized by Toll-like receptors (TLR2, 4 and 7).
Further, we developed and tested combination and dual-pronged treatment approaches: we demonstrated
efficacy of CPMV as solo-treatment as well as in combination with radiation, chemotherapy, immunomodulatory
drugs, and checkpoint inhibitors, amongst others. This proposal builds on this strong portfolio of data. Our first
goal is to focus on dual-pronged CPMV that combines its immunomodulatory and antitumor immunity properties
with checkpoint therapy (Aim 1). Checkpoint blocking antibodies are effective at removing inhibitory signals but
as monotherapy have variable and limited efficacy. In situ vaccination with CPMV increases tumor antigen
specific effector T cells and our preliminary data indicate that CPMV treatment synergizes with immune
checkpoint therapy. Next, we seek to develop targeted approaches that effectively concentrate systemically
administered CPMV in tumors and provide further therapy options to treat metastatic disease (Aim 2). S100A9-
targeted CPMV will be studied: expression of S100A9 (also known as myeloid-related protein 14 [MRP-14]), is
linked to inflammation and carcinogenesis. Higher S100A9 expression in breast cancer correlates with a worse
prognosis. S100A9 expression is an early event in tumorigenesis, enhancing tumor aggressiveness and
metastasis. In the TME, S100A9 is secreted to the extracellular matrix, making it a highly suitable target for
nanomedicine. Recognizing the potential of S100A9 as a pharmacologic target, we developed S100A9-targeted
CPMV that efficiently concentrates at sites of metastasis enabling potent efficacy preventing outgrowth of
metastases. Here we set out to detail the mechanisms of action and understand the pharmacology of S100A9-
targeted CPMV. Finally, the preclinical development will be substantially extended with veterinary clinical trials
in companion dogs with mammary tumors (Aim 3).
摘要
这份R01续签申请专注于三重阴性乳腺癌(TNBC),这是一种侵略性的生活-
预后差,复发和远处转移的可能性增加的威胁疾病。
癌症免疫治疗的进展表明,对患者免疫系统的调节可以
具有显著的抗肿瘤活性。最有希望的免疫治疗方法是那些
个性化并利用每个患者肿瘤中独特的新抗原。为了实现这个目标,我们
开发了一种植物病毒纳米颗粒免疫疗法,可以激活体内的天然免疫细胞
肿瘤微环境(TME)以启动适应性、系统性和持久的抗肿瘤免疫。
具体地说,瘤内注射豌豆花叶病毒(CPMV)在多只小鼠身上显示出强大的疗效
型号,包括TNBC。在患有乳腺癌的伴侣犬身上的试验也表明了强大的抗肿瘤效果。
在前一个供资周期中,我们对行动机制有了深入的了解,并证明
CPMV由病原体相关分子模式(PAMP)受体识别,PAMP受体检测危险信号
并激活先天免疫系统;具体地说,CPMV由Toll样受体(TLR2、4和7)识别。
此外,我们开发并测试了组合和双管齐下的治疗方法:我们演示了
CPMV单独治疗及与放化疗、免疫调节联合治疗的疗效观察
药物和检查站抑制剂等。这项建议建立在这一强大的数据组合之上。我们的第一次
目标是专注于结合了免疫调节和抗肿瘤免疫特性的双管齐下的CPMV
使用检查点疗法(目标1)。检查点阻断抗体在消除抑制信号方面是有效的,但
AS单一疗法疗效多变且有限。CPMV原位免疫可增加肿瘤抗原
特异性效应T细胞和我们的初步数据表明,CPMV治疗与免疫协同作用
检查点疗法。接下来,我们寻求开发有针对性的方法,有效地系统地集中精力
在肿瘤中实施CPMV,并为治疗转移性疾病提供进一步的治疗选择(目标2)。S100A9-
将研究靶向CPMV:S100A9(也称为髓系相关蛋白14[MRP-14])的表达,是
与炎症和癌症有关。S100A9在乳腺癌中的高表达与病情恶化相关
预后。S100A9的表达是肿瘤发生、增强肿瘤侵袭性和
转移。在TME中,S100A9被分泌到细胞外基质,使其成为非常适合的靶点
纳米医学。认识到S100A9作为药理靶点的潜力,我们开发了靶向S100A9
有效地集中在转移部位的CPMV,能够有效地防止肿瘤的生长
转移瘤。在这里,我们将详细介绍S100A9的作用机制,并了解其药理作用。
靶向CPMV。最后,随着兽医临床试验的进行,临床前开发将大幅延长
患有乳腺肿瘤的伴侣犬(目标3)。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cowpea Mosaic Virus (CPMV)-Based Cancer Testis Antigen NY-ESO-1 Vaccine Elicits an Antigen-Specific Cytotoxic T Cell Response.
- DOI:10.1021/acsabm.0c00259
- 发表时间:2020-07-20
- 期刊:
- 影响因子:4.7
- 作者:Patel BK;Wang C;Lorens B;Levine AD;Steinmetz NF;Shukla S
- 通讯作者:Shukla S
Development of a Virus-Like Particle-Based Anti-HER2 Breast Cancer Vaccine.
- DOI:10.3390/cancers13122909
- 发表时间:2021-06-10
- 期刊:
- 影响因子:5.2
- 作者:Hu H;Steinmetz NF
- 通讯作者:Steinmetz NF
Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis.
- DOI:10.1073/pnas.2221859120
- 发表时间:2023-10-24
- 期刊:
- 影响因子:11.1
- 作者:Chung, Young Hun;Ortega-Rivera, Oscar A.;Volckaert, Britney A.;Jung, Eunkyeong;Zhao, Zhongchao;Steinmetz, Nicole F.
- 通讯作者:Steinmetz, Nicole F.
Doxorubicin-Loaded Physalis Mottle Virus Particles Function as a pH-Responsive Prodrug Enabling Cancer Therapy.
- DOI:10.1002/biot.202000077
- 发表时间:2020-12
- 期刊:
- 影响因子:4.7
- 作者:Hu H;Steinmetz NF
- 通讯作者:Steinmetz NF
Isolation of Cowpea Mosaic Virus-Binding Peptides.
- DOI:10.1021/acs.biomac.1c00712
- 发表时间:2021-08-09
- 期刊:
- 影响因子:6.2
- 作者:Chan, Soo Khim;Steinmetz, Nicole F.
- 通讯作者:Steinmetz, Nicole F.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicole Franziska Steinmetz其他文献
Nicole Franziska Steinmetz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicole Franziska Steinmetz', 18)}}的其他基金
Dual-pronged nano-drug delivery using plant virus-like particles.
使用植物病毒样颗粒进行双管齐下的纳米药物输送。
- 批准号:
9982275 - 财政年份:2018
- 资助金额:
$ 36.52万 - 项目类别:
Dual-pronged nano-drug delivery using plant virus-like particles.
使用植物病毒样颗粒进行双管齐下的纳米药物输送。
- 批准号:
10224677 - 财政年份:2018
- 资助金额:
$ 36.52万 - 项目类别:
Dual-pronged nano-drug delivery using plant virus-like particles
使用植物病毒样颗粒的双管齐下纳米药物输送
- 批准号:
9372245 - 财政年份:2017
- 资助金额:
$ 36.52万 - 项目类别:
A theranostic approach for risk stratification and intervention of deep vein thrombosis.
深静脉血栓形成风险分层和干预的治疗诊断方法。
- 批准号:
9767271 - 财政年份:2017
- 资助金额:
$ 36.52万 - 项目类别:
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging
通过分子磁共振成像诊断和纵向监测转移性前列腺癌
- 批准号:
9208751 - 财政年份:2016
- 资助金额:
$ 36.52万 - 项目类别:
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging.
通过分子磁共振成像诊断和纵向监测转移性前列腺癌。
- 批准号:
9755062 - 财政年份:2016
- 资助金额:
$ 36.52万 - 项目类别:
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging.
通过分子磁共振成像诊断和纵向监测转移性前列腺癌。
- 批准号:
9629935 - 财政年份:2016
- 资助金额:
$ 36.52万 - 项目类别:
Engineering 'Grapevine Virus A' filaments for nanomedical applications
工程“葡萄病毒 A”细丝用于纳米医学应用
- 批准号:
9144385 - 财政年份:2015
- 资助金额:
$ 36.52万 - 项目类别:
Detection of lethal prostate cancer with macromolecule-based, EGFL-7 targeted MR imaging approach
使用基于大分子的 EGFL-7 靶向 MR 成像方法检测致命性前列腺癌
- 批准号:
8954282 - 财政年份:2015
- 资助金额:
$ 36.52万 - 项目类别:
Detection of lethal prostate cancer with macromolecule-based, EGFL-7 targeted MR imaging approach
使用基于大分子的 EGFL-7 靶向 MR 成像方法检测致命性前列腺癌
- 批准号:
9094573 - 财政年份:2015
- 资助金额:
$ 36.52万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Continuing Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Standard Grant
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Research Grant
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Fellowship
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Discovery Projects
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Research Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 36.52万 - 项目类别:
Discovery Projects